Abstract: Methods of treating joint damage in a subject eligible for treatment are provided involving administering an antagonist that binds to a B-cell surface marker, such as CD20 antibody, to the subject in an amount effective to slow progression of the joint damage as measured by radiography. Further provided are articles of manufacture useful for such methods.
Type:
Grant
Filed:
July 30, 2019
Date of Patent:
May 19, 2020
Assignees:
Genentech, Inc., F. Hoffmann-La Roche AG, Biogen Inc.
Inventors:
Mark Totoritis, Timothy Mark Shaw, Sunil Agarwal, David Yocum, Ariella Kelman
Abstract: The present invention relates to MASP-3 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-3 dependent complement activation.
Type:
Grant
Filed:
July 31, 2017
Date of Patent:
May 5, 2020
Assignee:
Omeros Corporation
Inventors:
W. Jason Cummings, Gregory A. Demopulos, Thomas Dudler, Larry W. Tjoelker, Christi L. Wood, Munehisa Yabuki
Abstract: Isolated antigen binding molecules that specifically bind to an anti-CD19 scFv comprising SEQ ID NO: 1 are provided. The antigen binding molecules can be used in the methods provided herein.
Abstract: Provided are antibodies that bind to: a sulfonated epitope of the protein Sclerostin, to Sclerostin portions comprising a sulfonated amino acid and to dimerized forms of Sclerostin. Further provided are compositions and peptides comprising a sulfonated epitope of sclerostin. Also provided by this invention are methods for production of such antibodies, both active and passive, and methods for identifying antibodies specific for sulfonation sites in Sclerostin and other antibodies which discriminate between sulfonated and unsulfonated forms of sclerostin. Physical and virtual screening processes are provided in this invention for identifying compounds which disrupt or inhibit sulfonation and the interaction between Sclerostin and binding partners. The antibodies and compositions of the present invention are useful in diagnostic and therapeutic applications directed to Sclerostin-related disorders.
Abstract: The present disclosure relates to compositions and methods for reducing immune tolerance associated with CAR T cell therapy. Embodiments of the present disclosure include isolated nucleic acid sequence comprising a nucleic acid sequence that encodes modified programmed cell death protein 1 (PD-1) and a nucleic acid sequence that encodes chimeric antigen receptor (CAR).
Abstract: Described herein are anti-PCSK9 antibody crystals, methods of making such antibody crystals and formulations comprising the antibody crystals.
Type:
Grant
Filed:
July 13, 2015
Date of Patent:
April 7, 2020
Assignee:
Amgen Inc.
Inventors:
Twinkle R. Christian, Christi L. Clogston, Timothy David Osslund
Abstract: A polypeptide comprising one or more sequences derived from CDR2 or CDR3 of a TREM-1 protein, characterised by the ability to treat, ameliorate, or lessen the symptoms of conditions including sepsis, septic shock or sepsis-like conditions and IBD.
Type:
Grant
Filed:
December 14, 2015
Date of Patent:
March 31, 2020
Assignees:
Bristol-Myers Squibb Company, Universite de Lorraine
Abstract: Compositions and methods relating to epitopes of sclerostin protein, and sclerostin binding agents, such as antibodies capable of binding to sclerostin, are provided.
Abstract: This provides pharmaceutical compositions that comprise a combination of an anti-cancer agent which is an first antibody and a second antibody. In some embodiments, the first antibody is an anti-Programmed Death-1 (PD-1) antibody. In certain embodiments, the composition is a fixed dose formulation. In certain embodiments, the composition is administered as a flat-dose. The disclosure also provides a kit for treating a subject afflicted with a disease, the kit comprising a dosage of any composition disclosed herein and instructions for using the composition in any of the disclosed methods for treating a disease.
Abstract: Methods of treating joint damage in a subject eligible for treatment are provided involving administering an antagonist that binds to a B-cell surface marker, such as CD20 antibody, to the subject in an amount effective to slow progression of the joint damage as measured by radiography. Further provided are articles of manufacture useful for such methods.
Type:
Grant
Filed:
April 15, 2019
Date of Patent:
October 22, 2019
Assignees:
Genetech, Inc., F. Hoffmann-La Roche AG, Biogen Inc.
Inventors:
Mark Totoritis, Timothy Mark Shaw, Sunil Agarwal, David Yocum, Ariella Kelman
Abstract: The invention provides scFv antibodies and monoclonal antibodies that bind to and decrease an activity of Carbonic Anhydrase IX (G250). Also provided are the methods of treating and/or preventing cancer, such as renal clear cell cancer. Also provided are methods of identifying a carbonic anhydrase IX (G250) protein. The invention additionally provides methods of modifying immune effector cells, and the immune effector cells modified thereby.
Type:
Grant
Filed:
May 9, 2017
Date of Patent:
October 22, 2019
Assignee:
DANA-FARBER CANCER INSTITUTE, INC.
Inventors:
Wayne A. Marasco, Agnes Lo, Chen Xu, Quan Zhu
Abstract: Monoclonal antibodies directed to ceramide that inhibit apoptosis are disclosed. Humanized and scFv versions of the antibodies are also disclosed. Methods for prevention or treatment of apoptosis in a subject by administration of the anti-ceramide antibodies are disclosed.
Type:
Grant
Filed:
August 7, 2015
Date of Patent:
October 22, 2019
Assignees:
Memorial Sloan Kettering Cancer Center, Ceramide Therapeutics
Abstract: Provided herein is a proprotein convertase subtilisin kexin type 9 (PCSK9)-specific binding protein that comprises unique complementary determining regions, that is capable of specifically binding to PCSK9, effectively inhibiting the function of PCSK9, lowering plasma LDL cholesterol level and that is useful in treating diseases associated with or impacted by the function of PCSK9.
Abstract: The present invention provides methods for treating a PCSK9-mediated disease or a PCSK9-mediated condition. Specifically, the invention relates to methods comprising the administration of a proprotein convertase subtilisin/kexin type 9 (PCSK9) antibody or antigen binding protein, in the absence of a statin, to a subject in need thereof.
Type:
Grant
Filed:
November 12, 2014
Date of Patent:
October 1, 2019
Assignees:
SANOFI BIOTECHNOLOGY, REGENERON PHARMACEUTICALS, INC.
Inventors:
Marie Baccara-Dinet, Laurence Bessac, Corinne Hanotin, Robert C. Pordy, William J. Sasiela, Jacques Rey
Abstract: This invention relates to novel phosphorylation sites in cardiac Troponin I that are associated with the onset of heart failure. The phosphorylation sites, i.e., serine 5, tyrosine 26, threonine 51, serine 166, threonine 181 and/or serine 199, can be used as biomarkers for (i) identifying subjects at risk for the development of heart failure, (ii) treating subjects having a higher than normal level of the biomarker, and (iii) monitoring therapy of a subject at risk for the development of heart failure. Also described are antibodies, reagents, and kits for carrying out a method of the present invention.
Type:
Grant
Filed:
February 17, 2011
Date of Patent:
August 27, 2019
Assignees:
CEDARS-SINAI MEDICAL CENTER, VU-VUMC IP MANAGEMENT BV
Inventors:
Pingbo Zhang, Jennifer E. Van Eyk, Anne M. Murphy, Ger Stienen, Jolanda van der Velden, Viola Kooij
Abstract: The invention provides a rabbit-derived immortal B-lymphocyte capable of fusion with a rabbit splenocyte to produce a hybrid cell that produces an antibody. The immortal B-lymphocyte does not detectably express endogenous immunoglobulin heavy chain and may contain, in certain embodiments, an altered immunoglobulin heavy chain-encoding gene. A hybridoma resulting from fusion between the subject immortal B-lymphocyte and a rabbit antibody-producing cell is provided, as is a method of using that hybridoma to produce an antibody. The subject invention finds use in a variety of different diagnostic, therapeutic and research applications.
Type:
Grant
Filed:
April 1, 2016
Date of Patent:
August 13, 2019
Assignee:
EPITOMICS, INC.
Inventors:
Robert Pytela, Weimin Zhu, Yaohuang Ke, Qi Qian, Harry C. Au